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Although depression has weak associations with several Type 2 diabetes mellitus (DM) outcomes, it is possible
that these associations are concentrated within certain patient subgroups that are more vulnerable to their effects. This
study tested the hypothesis that depression is related to glycaemic control and diabetes-related quality of life (DQOL) in




Participants (103 on insulin, 155 on oral glucose-lowering agents alone) with Type 2 DM were recruited from




































































 0.002). Neither effect was




The generally weak association between depression and glycaemic control is concentrated among patients
who are prescribed insulin. Similarly, the association between depression and illness quality of life is strongest in patients
prescribed insulin. Because this is not attributable to depression-related adherence problems, psychophysiological
mechanisms unique to this group ought to be carefully investigated. Clinicians might be especially vigilant for depression
in Type 2 DM patients who use insulin and consider its potential impact upon their illness course.
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In patients with Type 2 diabetes mellitus (DM), depression
is associated with poor glycaemic control, complications,
hospital admission and other poor outcomes [1–4]. While
statistically significant, these associations are generally quite
small in magnitude, typically explaining only about 2–8% of
the variance in diabetes outcomes. As a result, researchers have
sought to determine whether linkages with depression might
cluster within various patient subgroups defined by demo-
graphic or clinical characteristics.
Although age and ethnicity have been examined as factors
which may modify the link between depression and glycaemia,
the most replicated finding is that depressive symptoms seem
to play a role in patients with Type 1 DM, but not Type 2 DM
[5,6]. Potential explanations for this pattern include the
impact of neurohormonal factors related to both mood state
and blood glucose and the possible effects of antidepressant
medication on endocrine functioning. To date, there is no clear
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Another interesting possibility is that this pattern may be
primarily attributable to the relative complexity of the Type 1
diabetes regimen relative to the use of oral glucose-lowering
agents. Insulin use can be significantly more complex than
the use of oral therapies, requiring more frequent glucose
self-monitoring, dosage changes in response to fluctuations in
food intake or exertion and the use of both long-acting as well
as short-acting formulas. Compared with the use of oral
medication, the relatively complex behaviours involved in
insulin use would probably be more disrupted by depression
and some patients experience considerable psychological
difficulty with the transition to insulin [7], which may in turn
lead to depression. This overall association has received some
preliminary support. In unadjusted analyses of patients with
either Type 1 or Type 2 diabetes, depressive symptom severity
and glycaemic control were significantly associated in a sample









 0.28), but not among those with any of the less
intensive regimens [8]. However, it is unclear whether this
effect is consistent enough to exist in Type 2 DM per se and
analyses were not adjusted for potential confounders.
The study objective was therefore to build upon existing
work by testing the hypothesis that depression is related to
Type 2 DM outcomes in patients using insulin, but not among
those using oral glucose-lowering agents alone. To rigorously
test our hypothesis, we adjusted for potential confounders,
incorporated criterion-based classification of depression
presence and severity, considered subjective quality-of-life





interaction. Finally, we tested whether regimen adherence







Potential participants were identified using the administrative
and clinical databases of a large urban healthcare system in the
midwestern USA. Patients were eligible if they had Type 2 DM
as indicated by at least one of the following: (i) at least one
hospital admission with a diabetes-related ICD-9 code (250.x,
357.2, 362.0 or 366.41); (ii) at least two outpatient visits with
a diabetes-related ICD-9 code; or (iii) at least one prescription
for an oral glucose-lowering medication or monitoring supplies.
In order to be eligible, patients also had to be of either Caucasian
or African-American ethnicity, able to complete self-report




Eligible patients were mailed a study invitation letter, followed
by a recruitment telephone call from research staff (including
both African-American and Caucasian recruiters) for further
screening and enrolment scheduling. After informed consent,
participants attended a research appointment for assessment of
depressive symptoms, diabetes regimen adherence and self-care
behaviours, glycaemic control, demographic characteristics
and medical characteristics. All procedures were approved by




The presence of probable depressive disorder was assessed
with the Patient Health Questionnaire-9 (PHQ-9) [9], in which
respondents use a 4-point scale to indicate: ‘How often, over
the last 2 weeks, were you bothered by any of the following
problems?’ Its advantages over other available scales include its
brevity, reflection of the Diagnostic and Statistical Manual
(DSM-IV) criteria and strong evidence of criterion validity.
Using established cut-off points, the PHQ-9 has 88% sensitivity
and 88% specificity for interview-detected major depression.


















 15). Diabetes-related quality of life
(DQOL) was measured using the Problem Areas in Diabetes
instrument [10], a validated instrument that consists of 20
items covering emotional responses to diabetes rated on a 5-
point scale from which a total score is calculated. Medication





., which elicits information about the presence
of various forms of medication non-adherence and has
demonstrated concurrent and predictive validity and adequate
internal consistency [11]. Additional self-care behaviours (diet,
exercise, foot care and blood glucose monitoring) were assessed
with the Summary of Diabetes Self-Care Activities (SDSCA)
[12], which has adequate test–retest reliability, is sensitive to
change and is correlated with other measures of the same
constructs. Co-morbid medical illnesses were assessed by
abstracting electronic medical records using a checklist of 13
common medical illnesses used in prior primary care studies





measured with the DCA 2000 (GMI Inc., Ramsey, MN, USA),
which analyses capillary blood samples through a monoclonal
antibody method. Participants classified themselves using US
Census racial/ethnic categories. Socio-economic status (SES)
was assessed using the US Census Bureau Index of Socio-





Descriptive statistics were calculated to summarize study
variables. Variables with skewed distributions were rank
converted for analysis. Bivariate associations were conducted












-test analysis for categorical variables. Associations
between depression and the two outcomes (glycaemic control
and quality of life) were analysed using linear multiple regression
modelling. Independent variables were entered in three blocks
corresponding to illness and demographic control covariates,









 0.05. Interaction scores were calculated by
multiplying scores for regimen (0 for oral glucose-lowering
 




Medicine Depression and Type 2 DM outcomes •
 
 J. E. Aikens et al.
 
















agents alone, 1 for insulin) and depression level (non-depressed,






Of 1569 patients who received a study announcement by
post, 392 could not be reached for telephone solicitation
after multiple attempts. Another 695 were discovered to be
ineligible because they did not meet entry criteria on the basis
of medical (e.g. did not have diabetes) or demographic (i.e.
were neither African-American nor Caucasian) factors,
leaving 482 patients. Of these, 37 patients declined participation
by means of returning the enclosed postcard and 445 were
reached for telephone solicitation, 273 of which consented to
the study. Combining those who declined by telephone or
post, 57% of 482 ostensibly eligible patients were recruited.
Consent was unrelated to age and gender, although African-







 0.025). Of those recruited, 258 (95%) provided
complete data and were thus analysable cases. Attrition was

















 0.023), but not with ethnicity, gender,
depression SES, DQOL or adherence behaviours. The final
sample was demographically and medically diverse (Table 1).
Half of the participants were female, 55% were African-
American, ages ranged from 27 to 88 years, 40% were prescribed
insulin, diabetes duration ranged from 1 to 60 years and 21%
had at least two significant co-morbid medical conditions.
 
Preliminary analysis of bivariate associations
 
Table 1 shows sample characteristics by regimen. Compared
with participants on oral glucose-lowering agents alone, those









and had significantly longer diabetes duration, poorer glycaemic




Table 2 contains the results of multivariable regression analyses
of glycaemic control. After adjusting for demographics and
medical covariates (Block 1), there was a significant associa-






 0.033) in the expected direction. The interaction term












 coefficient) between depression and glycaemic






 0.356) for participants on oral glucose-





















 0.0003). The interaction effect is depicted in Fig. 1. The
same pattern of significant findings emerged when depression
was analysed as a continuous dimension of symptom severity
rather than as a three-category variable.
Table 2 also contains the results of the analysis of DQOL as
an outcome of the same predictor variables, which showed very




 depression interaction term were significant. Regimen-
stratified follow-up analyses indicated that the adjusted
association between depression and quality of life was significant








 0.005), but that
the coefficient for those on insulin was significantly greater






















The interaction effect is depicted in Fig. 2.
 
Test for mediation by adherence
 
Both of the above analyses were then re-conducted to determine
whether the depression main effects or interactions were
Table 1 Demographic and medical characteristics, by regimen
Variable
Mean ± SD or per cent
PPooled (n = 258) On oral agent alone (n = 155) On insulin (n = 103)
Age (years) 57.2 ± 8.4 57.9 56.3 0.131
Gender (female; %) 49.2 51.3 46.1 0.415
African-American (%) 55.4 49.7 64.1 0.023
Socio-economic status index 65.0 ± 17.5 64.3 ± 18.0 66.0 ± 16.7 0.448
Diabetes duration (years) 10.9 ± 8.2 9.0 ± 7.0 13.6 ± 9.1 < 0.001
Two or more co-morbid medical conditions (%) 20.9 19.1 23.8 0.371
Medication adherence 0.8 0.8 0.8 0.999
HbA1c (%) 7.59 ± 1.62 7.38 ± 1.54 7.91 ± 1.74 0.005
Depressive symptom severity (PHQ-9 total) 5.5 ± 4.7 5.0 ± 4.1 6.32 ± 5.4 < 0.001
Diabetes quality of life (PAID total) 21.3 ± 16.3 19.6 ± 16.8 24.0 ± 21.1 0.068
HbA1c, glycated haemoglobin; PAID, Problem Areas in Diabetes; PHQ-9, Patient Health Questionnaire-9; SD, standard deviation.
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mediated by adherence, by including adherence main effects in
both of the above multivariate models. Although medication





























































 0.53 and 0.50,
respectively). Thus, mediation by medication non-adherence
was not supported. Exploratory analyses of other adherence
behaviours showed similar results.
Because insulin therapy is typically required for patients
who are chronically hyperglycaemic despite adequate trials
of oral medication, we considered whether the significant





the group using oral glucose-lowering agents alone. However,
Table 2 Multivariable ordinary least squares (OLS) regression analysis of diabetes outcomes
Dependent variable Independent variables R2 change P Standard β P
Glycaemic control (HbA1c ) Block 1 0.05 0.005
n = 258 Gender* –0.11 0.093
R2 total = 0.11 Ethnicity† 0.13 0.042
P < 0.001 Diabetes duration 0.14 0.024
Block 2 0.03 0.018
Regimen‡ 0.10 0.144
Depression§ 0.13 0.033
Block 3 0.03 0.002
Regimen × depression 0.55 0.002
Diabetes quality of life (PAID) Block 1 0.04 0.010
n = 255 Gender* 0.21 0.001
R2 total = 0.28 Ethnicity† 0.01 0.990
P < 0.001 Diabetes duration 0.04 0.547
Block 2 0.21 < 0.001
Regimen‡ 0.04 0.493
Depression§ 0.45 < 0.001
Block 3 0.03 0.001
Regimen × depression 0.52 0.001
*Coded as male = 0, female = 1.
†Coded as Caucasian = 0, African-American = 1.
‡Coded as on oral glucose-lowering agent alone = 0, on insulin = 1.
§Coded as non-depressed = 0, mild depression = 1, moderate or severe depression = 2.
HbA1c, glycated haemoglobin; PAID, Problem Areas in Diabetes.
FIGURE 1 Median glycaemic control by 
regimen and depression level.
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the same pattern of statistically significant interactions emerged
when the analyses excluded participants with HbA1c values
≤ 6.0 or ≥ 10.0%.
Discussion
To summarize, the findings indicate that, in patients using
insulin, depression was associated with poorer glycaemic
control and quality of life, whereas this was not the case for
those who were on oral medications alone. Our findings suggest
that the relatively weak association between depressive
symptoms and Type 2 DM outcomes found in previous studies
may be as a result of the tendency for researchers to combine
two subgroups in which depression plays a different role;
i.e. patients who use insulin with those who do not. There
are several plausible explanations for this result, only some
of which can be addressed within this study. For example,
the observed differences may be because of regimen-specific
behavioural mechanisms. First, to the extent that depression
disrupts medication adherence [16,17], it seems plausible that
this is more likely for patients prescribed insulin, which is
a more complex regimen and therefore probably more
burdensome than taking oral medication alone. Second, we
would speculate that glycaemic control would be more disrupted
by a few missed injections than a few missed oral medication
doses. However, mediation analyses indicated that, although
poor adherence occurred with both regimens, it did not
account for the differences by regimen.
A second possible explanation relates to the psychological
impact of insulin therapy. Patients ascribe significant negative
meaning to the concept of requiring injections [7,18,19], which
increases the influence of depressed mood upon outcomes,
particularly quality of life. However, the depression–outcome
association appears to exist in diabetic patients who do not
use insulin [17,20]. If exogenous insulin had some directly
depressogenic effect on brain function then this could explain
the findings. Once depression is present, pathological processes
such as hypercortisolism or activation of inflammatory
mediators may further worsen diabetes outcomes.
Third, regimen type is a direct reflection of diabetes severity
and duration. Because insulin therapy is typically prescribed when
glucose cannot be controlled through oral glucose-lowering
agents alone [21], insulin therapy is an obvious marker of
more advanced diabetes. Both depression and severe diabetes
may be associated with neurohormonal abnormal levels of
cortisol and catecholamines [22]. We would further speculate
that, as blood glucose becomes more labile, it becomes more
strongly related to psychological factors. We previously
reported in Type 1 diabetes that psychosocial factors such as
daily stress are more strongly related to blood glucose lability
than absolute levels of blood glucose [23].
The study results should be generalized with caution
because, even although the sample was demographically
diverse, enrolment occurred within one health system.
Although the measure and its cut-off points used to classify
probable depression were originally validated against psychiatric
interviews, we did not verify depression presence by structured
interview and therefore some psychiatric misclassification may
have occurred [24]. The validity of self-reported adherence
has often been questioned, because it may lead to inflated
estimates. However, self-report measures of medication
adherence show moderate-to-high concordance with other
measures of medication adherence [25]. For example, in a
prior study of antidepressant adherence, we found that
self-reported adherence agreed with pharmacy refill data 72%
of the time and was unassociated with social desirability bias
[13].
The observed associations might be explained by an
unmeasured factor such as the absolute level of exposure to
exogenous insulin, the subjective burden of using insulin, the
FIGURE 2 Mean PAID score by regimen and 
depression level.
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personal meaning of requiring insulin for diabetes control or
the number of complications [26,27]. Another limitation is
that the measures of depression and glycaemic control reflect
different time intervals (2 weeks vs. 8–12 weeks respectively),
which could weaken observed associations. Finally, the
cross-sectional observational study design does not allow
causal inference between diabetes and depression and therefore
we cannot determine the directionality of associations between
mood and diabetes outcomes.
In closing, the findings imply that the association between
depression and Type 2 DM outcomes exists only in patients
who are prescribed insulin. This effect is not mediated by
medication non-adherence, making it unlikely that depression-
related insulin omission explains the association. Other
potential mechanisms should be carefully studied. These
include the potential depressogenic effects of poor glycaemic
control and the existence of some common biological, psycho-
logical or healthcare factor that might cause poor outcomes in
both depression and diabetes. Clinicians who provide diabetes
care might be especially vigilant in terms of depression
screening and management for diabetic patients who are
prescribed insulin, inviting patients to discuss the personal
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